GRIFOLS

ALPHA-1
FOUNDATION

Grifols Awards One Million Dollar Grant to Support the Alpha-1 Foundation's John W. Walsh Research Fund

Honoring the memory of John W. Walsh, co-founder of the Alpha-1 Foundation, reaffirming a shared commitment to finding a cure for people with Alpha-1

Washington, DC June 24, 2017 — Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, will award a one million dollar grant to support the John. W. Walsh Research Fund, the Foundation's peer-reviewed research program to advance the scientific and clinical understanding of Alpha-1 Antitrypsin Deficiency (AATD) to help find the cure. The Research Fund is a program of the Alpha-1 Foundation working to fulfill John W. Walsh's mission of finding a cure for AATD. The announcement was made at the 26th Annual National Education Conference for Alpha-1 in Chicago as part of a tribute to Walsh, the Foundation's co-founder and leader for more than two decades, who passed away on March 7.

"John W. Walsh was an inspirational leader and visionary who dedicated his life to finding a cure for alpha-1. His passion and tireless energy paved the way for the Foundation to become an internationally recognized patient organization which helped drive research and educational programs worldwide. He was the 'impatient patient' whose determination positively impacted the Alpha-1 community on a global level," commented Gregory Rich, President and CEO of Grifols North America Operations.

Alpha-1 Foundation President and CEO Henry R. Moehring said, "We are grateful to Grifols for their amazing gift to honor John's legacy and for their unwavering support to the Alpha-1 community. This grant will go a long way in helping researchers to continue the Foundation's mission to find a cure."

Current evidence suggests that there are at least 100,000 people with AATD in the United States. AATD is a genetic inherited condition passed from one abnormal gene from each parent, which can cause liver damage and is the most common known genetic risk factor for Chronic Obstructive Pulmonary Disease (COPD).

The John W. Walsh Research Fund aims to promote research that will eventually result in the improved health of individuals with AATD, with a focus on the lung and liver disease of the deficiency. The program supports basic science and clinical research, improved understanding of the pathogenesis of the clinical manifestations of AATD, the development and testing of treatments for the disease, bioethics and social research, and the promotion of education of members of the medical community regarding AATD.

This announcement is a continuation of the Grifols longstanding commitment to improving the lives of patients around the world. Grifols actively supports programs and services that promote education, disease awareness, and patient advocacy efforts in order to improve the diagnosis and treatment of disease. Patients inspire the Company's mission to advance the discovery and development of innovative protein therapies that extend and enhance lives. Grifols continually strives to develop new and better products and services to improve our patients' health and wellbeing and proudly supports the Alpha-1 Foundation's ability to fund important research that will bring them closer to a cure.

For more information about The Alpha-1 Foundation visit: https://www.alpha1.org/.

About Grifols

Grifols is a global healthcare company and industry leader with more than 75-year in the development of life-saving medicines derived from human plasma that treat many rare and chronic conditions. Our mission is to improve the health and well-being of people around the world by producing treatments for patients and by providing hospitals, pharmacies, and healthcare professionals the tools and resources they need to deliver expert medical care.

The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of over 170 plasma donation centers in the U.S., and is a leading producer of plasma-derived medicines.

About The Alpha-1 Foundation

The Alpha-1 Foundation is a not-for-profit Florida corporation founded in 1995 by John Walsh, Sandy Lindsey and Susan Stanley, three people diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1). The three founders have since passed away, Susan Stanley in 2000, Sandy Lindsey in 2002, and Walsh on March 7, 2017. The Alpha-1

Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

The Foundation has developed a solid infrastructure and has fostered collaborations with investigators throughout the United States and Europe, working closely with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), people affected by Alpha-1 and the pharmaceutical industry to expedite the development of improved therapies.